the benefits of adjuvant cdk4/6 and parp inhibition in breast cancer
Published 1 year ago • 203 plays • Length 3:35Download video MP4
Download video MP3
Similar videos
-
2:06
unmet needs and cdk4/6 inhibitors in hr /her2- early breast cancer
-
2:11
the use of frontline cdk4/6 inhibitors endocrine therapy in metastatic breast cancer
-
0:57
evaluating the benefits of selective cdk4 inhibition in hr /her2- breast cancer
-
1:51
reflecting on the use of cdk4/6 inhibitors in hr breast cancer
-
6:36
adjuvant cdk4/6 inhibition in early-stage hr-positive breast cancer | ruth o'regan
-
3:30
final results from pallas: adjuvant palbociclib in hr /her2- early breast cancer
-
5:01
cdk4/6 inhibitors: sequencing endocrine therapy for metastatic breast cancer
-
4:43
a retrospective study of outcomes with ven-based treatment in cbtki-treated, chemotherapy-naïve cll
-
1:04
biomarkers to help predict response to cdk4/6 inhibitors
-
4:54
monarch 3 study: cdk4/6 inhibitors in the treatment of metastatic breast cancer
-
2:07
remaining questions regarding the use of frontline cdk4/6 inhibitors and endocrine therapy
-
5:47
monarche and pallas: a tale of two cdk4/6 inhibitors | george sledge jr
-
8:28
cdk4/6 inhibition in breast cancer
-
58:22
adjuvant cdk4 and 6 inhibition to prevent recurrences in high-risk hr /her2- early breast cancer
-
4:52
future directions: cdk4/6 inhibitors in breast cancer
-
1:58
impact of cdk4/6 inhibitors on hr-positive, her2-negative advanced breast cancer
-
3:23
adjuvant cdk4/6 inhibition: when it will become routine
-
20:19
expert discussion on cdk 4/6 inhibition in breast cancer
-
4:17
cdk4/6 inhibitors & endocrine therapy in breast cancer